Cargando…

CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections

Detalles Bibliográficos
Autores principales:	Kwa, S, Sadagopal, S, Hong, J, Gangadhara, S, Basu, R, Lai, L, Iyer, S, Araki, K, Earl, PL, Wyatt, L, Villinger, F, Moss, B, Ahmed, R, Amara, RR
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442088/ http://dx.doi.org/10.1186/1742-4690-9-S2-P365

Ejemplares similares

GM-CSF co-expressing DNA/MVA vaccine, prevention of acquisition by two series of SIVE660 challenges followed by a series of SIV251 challenges
por: Robinson, H, et al.
Publicado: (2012)

OA07-03. Influence of preexisting vaccinia immunity on a DNA/MVA SIV vaccine, decreased cellular immunity but enhanced control of a pathogenic SIV challenge
por: Kannanganat, S, et al.
Publicado: (2009)

Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys
por: Barouch, Dan H., et al.
Publicado: (2012)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

DNA/MVA Vaccines for HIV/AIDS
por: Iyer, Smita S., et al.
Publicado: (2014)

A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal Vaccination
por: Huang, Xiaoxing, et al.
Publicado: (2009)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIV(mac251) Rectal Challenge
por: Tuero, Iskra, et al.
Publicado: (2015)

Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals
por: Zaeck, Luca M., et al.
Publicado: (2022)

Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4
por: Welles, Hugh C., et al.
Publicado: (2022)

Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2016)

Antibody-dependent cellular cytotoxicity, infected cell binding and neutralization by antibodies to the SIV envelope glycoprotein
por: Grunst, Michael W., et al.
Publicado: (2023)

Glycerol monolaurate prevents mucosal SIV transmission
por: Li, Qingsheng, et al.
Publicado: (2009)

Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center
por: Eslamizar, Leila, et al.
Publicado: (2021)

Software for Data Acquisition System of the Spherical Neutral Detector
por: Achasov, M N, et al.
Publicado: (2003)

Evidence for Env-V2 sieve effect in breakthrough SIV (MAC251) infections in rhesus monkeys vaccinated with Ad26/MVA and MVA/Ad26 constructs
por: Sina, S, et al.
Publicado: (2012)

Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals
por: Greenier, Jennifer L, et al.
Publicado: (2005)

T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers
por: Arunachalam, Prabhu S., et al.
Publicado: (2020)

The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection
por: Charles, Tysheena P., et al.
Publicado: (2021)

Targeting α4β7 integrin reduces mucosal transmission of SIV and protects GALT from infection
por: Byrareddy, Siddappa N., et al.
Publicado: (2014)

DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge
por: Nigam, Pragati, et al.
Publicado: (2007)

P04-47. High-titer autologous and heterologous neutralizing antibody activity in acute SIV-infection
por: Schweighardt, B, et al.
Publicado: (2009)

Protection against High-Dose Highly Pathogenic Mucosal SIV Challenge at Very Low Serum Neutralizing Titers of the Antibody-Like Molecule CD4-IgG2
por: Poignard, Pascal, et al.
Publicado: (2012)

V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques
por: Styles, Tiffany M., et al.
Publicado: (2022)

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys
por: Johnson, Philip R, et al.
Publicado: (2009)

Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail
por: Kuwata, Takeo, et al.
Publicado: (2013)

Limited Impact of Passive Non-Neutralizing Antibody Immunization in Acute SIV Infection on Viremia Control in Rhesus Macaques
por: Nakane, Taku, et al.
Publicado: (2013)

Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques
por: Ventura, John D., et al.
Publicado: (2022)

HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
por: Capucci, Silvia, et al.
Publicado: (2017)

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
por: Fathi, Anahita, et al.
Publicado: (2022)

Cholera toxin B scaffolded, focused SIV V2 epitope elicits antibodies that influence the risk of SIV(mac251) acquisition in macaques
por: Rahman, Mohammad Arif, et al.
Publicado: (2023)

Systemic administration of an HIV 1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization
por: Fouda, Genevieve G., et al.
Publicado: (2016)

Epithelium-Innate Immune Cell Axis in Mucosal Responses to SIV
por: Shang, L., et al.
Publicado: (2016)

Intestinal damage precedes mucosal immune dysfunction in SIV infection
por: Hensley-McBain, Tiffany, et al.
Publicado: (2018)

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
por: Gilbert, Peter B., et al.
Publicado: (2022)

Analysis of Acquisition of COVID-2019 Neutralizing Antibodies in Organ Transplant Recipients
por: Akimoto, Shuji, et al.
Publicado: (2023)

P04-41. Kinetics of antibody neutralization and viral evolution following envelope vaccination in SIV-infected rhesus monkeys
por: Basavapathruni, A, et al.
Publicado: (2009)

Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus
por: Ba, Lei, et al.
Publicado: (2007)

Correction: HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
por: Capucci, Silvia, et al.
Publicado: (2023)

Live Attenuated Rev-Independent Nef¯SIV Enhances Acquisition of Heterologous SIVsmE660 in Acutely Vaccinated Rhesus Macaques
por: Byrareddy, Siddappa N., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_chmee3gpd058881lmohealourf